OTCPK:VXLL.F

Stock Analysis Report

Executive Summary

Vaxil Bio Ltd., an immunotherapy biotech company, engages in the research and development of immunotherapies for cancer and infectious diseases in Israel.

Rewards

Earnings have grown 11.6% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Does not have a meaningful market cap ($12M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

+ 1 more risk


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has Vaxil Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VXLL.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

257.1%

VXLL.F

-0.5%

US Biotechs

0.06%

US Market


1 Year Return

163.8%

VXLL.F

13.4%

US Biotechs

19.4%

US Market

Return vs Industry: VXLL.F exceeded the US Biotechs industry which returned 13.4% over the past year.

Return vs Market: VXLL.F exceeded the US Market which returned 19.4% over the past year.


Shareholder returns

VXLL.FIndustryMarket
7 Day257.1%-0.5%0.06%
30 Day212.5%1.1%1.1%
90 Day178.8%8.8%8.9%
1 Year163.8%163.8%14.3%13.4%21.9%19.4%
3 Year42.9%42.9%24.0%20.6%48.9%39.3%
5 Yearn/a2.7%-2.1%71.9%53.1%

Price Volatility Vs. Market

How volatile is Vaxil Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Vaxil Bio undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Vaxil Bio is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Vaxil Bio has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of VXLL.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Vaxil Bio regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Vaxil Bio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vaxil Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Vaxil Bio performed over the past 5 years?

11.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VXLL.F is currently unprofitable.

Growing Profit Margin: VXLL.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VXLL.F is unprofitable, but has reduced losses over the past 5 years at a rate of 11.6% per year.

Accelerating Growth: Unable to compare VXLL.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VXLL.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (64%).


Return on Equity

High ROE: VXLL.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Vaxil Bio's financial position?


Financial Position Analysis

Short Term Liabilities: VXLL.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: VXLL.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: VXLL.F is debt free.

Reducing Debt: VXLL.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: VXLL.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: VXLL.F has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VXLL.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VXLL.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.9% each year.


Next Steps

Dividend

What is Vaxil Bio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate VXLL.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VXLL.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VXLL.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VXLL.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VXLL.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average board tenure


CEO

David Goren 0

1.4yrs

Tenure

CA$128,000

Compensation

Mr. David Goren has been Chief Executive Officer of Vaxil Bio Ltd. since September 2018 and has been its Chairman since August 2019. He also serves as Director of Vaxil Bio Ltd. Since September 04, 2018. M ...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD96.53K) is below average for companies of similar size in the US market ($USD519.76K).

Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.


Board Members

NamePositionTenureCompensationOwnership
David Goren
Chairman1.4yrsCA$128.00kno data
Gadi Levin
CFO & Director3.3yrsCA$59.00k0.47% CA$44.3k
Riva Kovjazin
Senior Scientist & Member of Scientific Advisory Board0yrsno datano data
Ari Kellen
Director & Member of Scientific Advisory Board2.2yrsno data5.61% CA$526.3k
Shawn Langer
Director & Member of Scientific Advisory Board2.2yrsno data5.61% CA$526.3k

2.2yrs

Average Tenure

Experienced Board: VXLL.F's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.5%.


Top Shareholders

Company Information

Vaxil Bio Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vaxil Bio Ltd.
  • Ticker: VXLL.F
  • Exchange: OTCPK
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$12.450m
  • Listing Market Cap: CA$9.389m
  • Shares outstanding: 88.93m
  • Website: https://vxlbio.com

Location

  • Vaxil Bio Ltd.
  • 3400 One First Canadian Place
  • Toronto
  • Ontario
  • M5X 1A4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VXLTSXV (TSX Venture Exchange)YesCommon SharesCACADMar 2016
VXLL.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2016

Biography

Vaxil Bio Ltd., an immunotherapy biotech company, engages in the research and development of immunotherapies for cancer and infectious diseases in Israel. The company’s lead product is ImMucin that has completed a Phase1/2 clinical trial, which is used for the treatment of multiple myeloma. It is also involved in developing a tuberculosis vaccine/treatment. The company was founded in 2006 and is headquartered in Toronto, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 02:40
End of Day Share Price2020/02/18 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.